|Bid||7.56 x 900|
|Ask||7.78 x 2200|
|Day's range||7.54 - 8.72|
|52-week range||7.53 - 52.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
NEW YORK, December 04, 2021--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Zymergen Inc. (NASDAQ: ZY) on behalf of long-term stockholders following a class action complaint that was filed against Sequential on August 4, 2021. Our investigation concerns whether the board of directors of Sequential have breached their fiduciary duties to the company.
LOS ANGELES, November 11, 2021--The Law Offices of Frank R. Cruz Announces Investigation of Zymergen Inc. (ZY) on Behalf of Investors
LOS ANGELES, November 10, 2021--Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, today announces that it has commenced an investigation of potential claims against the board of directors of Zymergen Inc. ("Zymergen" or the "Company") (NASDAQ: ZY) concerning whether the board of directors breached its fiduciary duties to Zymergen shareholders.